INSTITUTION PROFILE
ASCO
— The clinical oncology society where pivotal Phase III cancer trial results are often presented to the world
ASCO is the center of cancer patients. There is no authority to approve the drug, but the annual meeting opens in Chicago every year around June A place where the results of late clinical trials of anticancer drugs are published for the first timeIt depends on the schedule of the development announcement of pharmaceutical companies. More about ASCOMedical guidelines that show how to use approved drugs and testsI made it. In this article, ASCOHow much does drug discovery and DDS affect?We will organize the annual meeting, academic journal, and medical guidelines from three routes.
- ASCO in 30 seconds
- What kind of organization is the type of influence?
- What is DDS?
- Scope of influence (authorization and region)
- Companies and organizations involved
- Future Prospects
- Glossary/Source/Ins ment and Source Response Table
1. ASCO in 30 seconds
、s submitted to ASCO until ASCO is publishedPrivacy PolicyHome The relevant parties, including the above client (corporate), can also clarify the information before publishingIt is prohibited to use for securities trading FactsHome In other words, ASCO is an important test result for companies developing anticancer drugsWhen and how to make the worldHowever, determining whether or not to approve is a national regulatory authority,ASCO itself has no direct authority to approval。
2. What kind of organization is the type of influence?
The drug discovery and DDS articles are not sold by yourself. instead ofWhat pathways will affect the industry?is divided into four types.
3. What is DDS?
How ASCO is involved in drug discoveryAnnual Meeting、Journal、Medical Guidelinedivided into three Facts。
| Activities | Size | Home | Relationship with Drug and DDS |
|---|---|---|---|
| Annual Meeting (2026) | May 29 - June 2, online with Chicago More than 7,000 abstracts | Regular abstracts will be published on May 21st. Late-Breaking abstracts (LBA) will be released at 7am on the day of presentation. | 5 Plenary LBAs (LBA1 to LBA5 are phase III trials, resulting from Atezolizumab, Atezolizumab, Cabozantinib, Icotegrab, RET (ON) in Toracostomy RAS (ON) in Thoracostomy). |
| Late-Breaking Record | The deadline for submitting data is January 27, 2026. | No spare data at the time of the deadlinePhase II and Phase III trialetc. First, secure the frame with an abstract without the result column, and extract the data from the other | Companies can set the test analysis schedule according to this deadline |
| Journal | Journal of Clinical Oncology | JCO Precision Oncology | One of the authors of the phase III study program. The publication of conference presentations and papers at the same time will be adjusted by the author. |
| Medical Guideline | Recommended by disease and treatment methods | Created by a multi-patient expert committee including patient support groups. GRADE evaluates the basis and sets the limit to the conflict of interest with the company. ASCO-led creation costs | How to use approved drugs or testsindicate to the doctor. In 2022, the report on the use of biosimilars in the cancer area was published. |
ASCO covers LBA,practice-changingIt is narrowed down to important results. However, the presentation at the conference does not have been reviewed by the regulatory authorities, and the application for approval is done separately by the company. As a flow, the results were first published at the annual meeting and reviewed as a (2) paper. (3) The regulatory authority determines the approval, (4) The order of incorporating the medical guidelines such as ASCO for the approved usage The evaluation of this paperHome This article does not track when an individual LBA was subsequently approved in any country Undetermined / Future。
4. Scope of influence (authorization and region)
| What ASCO has | Not having | |
|---|---|---|
| Annual Meeting, LBA certification, date and time of publicationDe permissions. Permission to determine the recommendation of medical guidelines | Authorization of drugs, safety measures, and reimbursement of insurance. Permission to force guidelines to a doctor | |
| Region | HomeUSAHome The annual meeting of 2025 is held from 166 countries. "Global Guidelines" that consider the difference of resources | Permission to directly change medical guidelines and insurance systems in each country |
| A group of companies and research groups that conduct clinical trials, such as oncologists, and media agencies (preliminary briefing for certified journalists) | Other areas of cancer | |
| Size | More than 50,000 members, 20 directors, 30 permanent committees | Number of employees and financial figures are not confirmed in this article |
166 countries2025 yearsThe number of annual meeting of ASCO is listed on the page of the annual meeting. The number of participants in 2026 was not listed on the official page of this article. Undetermined / FutureHome In addition, the number of countries in which the member lives is 150 or more in the summary page, and the member's page is written with 170 or more and does not match Facts。
5. Companies and organizations involved
Sponsors of the 2026 Annual Meeting
| Sponsorship category (ASCO notation) | Company | How to read |
|---|---|---|
| Sponsorship Donors（Platinum） | Daiichi Sankyo, Nov)s | category. Not published |
| Sponsorship Donors（Gold・Silver） | Bristol Myers Squibb（Gold）、Gilead and Kite・Lilly（Silver） | HELSINN |
| Annual Meeting Track Donors | Merck & Co.（Conqueror）、AstraZeneca・BioNTech・Daiichi Sankyo・Lilly・Novartis（Visionary） | Donation to Field |
* Sponsorships support the operation of the society, and are separate procedures from the society. In the creation of ASCO guidelines, there is a limit to the financial relationship that members can have with the company.
6. Future Prospects
| Read | Primary Information | |
|---|---|---|
| Companies that develop anticancer drugs will analyze and announce critical phase III trialsASCO deadlines and envelopesContact Us | The 2027 Annual Meeting was held in Chicago from June 4-8. The deadline for the abstract is January 26, 2027, and the deadline for LBA is March 8, 2027. s are confidential and are prohibited to use them for securities transactions. | |
| The third phase data of the drug of the mechanism of new action will continuePlenary LBA Core | All 5 Plenary LBAs in 2026 are phase III trials, including RAS (ON) in)tors | |
| The impact of ASCO’s medical guidelines is also in a country with limited resourcesGlobal GuidelinesClose | ASCO is creating a Global Guidelines that considers differences in resources |
7. Glossary
- LBA (Late-Breaking ))
- A mechanism to secure important results that are not matched to the deadline of normal abstracts, and to extract data from the beginning. It will be published in the morning of the presentation.
- Embargo
- The decision to ban the contents until the specified day. ASCO does not allow the use of securities transactions prior to publication.
- Plenary
- All participants The most prominent annual meeting is held.
- GRADE
- International framework to evaluate the accuracy and recommended strength of the basis of the above. Used in the creation of ASCO guidelines.
- Non-sampling test
- Clinical trials that are assigned to the treatment group, such as the patient's bleeding. It is possible to compare low bias.
8. Source
- ASCO About ASCO https://www.asco.org/about-asco
- ASCO ASCO Overview (more than 50,000 members, about one third is more than 150 countries outside the United States, 20 directors, 30 permanent committees, Conquer Cancer, 。(c)(3)). https://www.asco.org/about-asco/asco-overview
- ASCO Membership (approximately 1/3 of 50,000 members) https://www.asco.org/get-involved/membership
- ASCO ASCO Annual Meeting (Over 44,000 participants in 2025, 166 countries, 2027, 2026 sponsors) https://www.asco.org/annual-meeting
- ASCO New Research Highlights Role of Lifestyle Factors, New Treatment Strategies in Cancer Care More than 7,000 abstracts, publication date and time of LBA, Plenary LBA1~ https://www.asco.org/about-asco/press-center/news-releases/new-research-highlights-lifestyle-treatment-strategies-2026-annual-meeting
- ASCO Late-Breaking Data) Guidelines for 2026 https://www.asco.org/annual-meeting/abstracts-presentations/submission-details/late-breaking-data-submission-guidelines
- ASCO Frequently Policies - Frequently Questions https://www.asco.org/annual-meeting/abstracts-presentations/abstract-policies-embargoes-exceptions/faqs
- ASCO Dates to Know (2027 abstracts and LBA deadlines, June 4-8, 2027). https://www.asco.org/annual-meeting/dates-know
- ASCO Journal Articles https://www.asco.org/journals
- ASCO Guidelines (recommended by disease and means of treatment, how to use approved medical products, multi-disciplinary expert committee) https://www.asco.org/practice-patients/guidelines
- ASCO Guideline Methodology (GRADE, upper limit of conflict of interest, ASCO burden of creation costs, Global Guidelines, 2022 biosimilar report). https://www.asco.org/practice-patients/guidelines/guideline-methodology
9. Response table of claims and sources
| Content | ||
|---|---|---|
| Established in | Facts | Source 1 https://www.asco.org/about-asco |
| More than 50,000 members and about one third are outside the U.S. (150+ countries), 20 directors, 30 permanent committees, Conquer Cancer, Public Charity | Facts | Source 2 https://www.asco.org/about-asco/asco-overview |
| 170 or more of the members | Facts | Source 3 https://www.asco.org/get-involved/membership |
| Over 40,000 participants in 2025, 166 countries and 2026 companies | Facts | Source 4 https://www.asco.org/annual-meeting |
| 2026, more than 7,000 abstracts, publication date and time of the abstract and LBA, content of Plenary LBA1-5, place of origin | Facts | Source 5 https://www.asco.org/about-asco/press-center/news-releases/new-research-highlights-lifestyle-treatment-strategies-2026-annual-meeting |
| Deadline for 2026 | Facts | Source 6 https://www.asco.org/annual-meeting/abstracts-presentations/submission-details/late-breaking-data-submission-guidelines |
| Confidentiality, Envergo, Prohibition of Use for Securities Transactions, concurrent posting of disclosure | Facts | Source 7 https://www.asco.org/annual-meeting/abstracts-presentations/abstract-policies-embargoes-exceptions/faqs |
| 2027 | Facts | Source 8 https://www.asco.org/annual-meeting/dates-know |
| JCO and JCO | Facts | Source 9 https://www.asco.org/journals |
| Treatment of the use of medical products approved by the medical guidelines and created by a multi-disciplinary committee | Facts | Source10 https://www.asco.org/practice-patients/guidelines |
| GRADE, upper limit of conflict of interest, ASCO burden of creation costs, Global Guidelines, Biosimilar Report | Facts | Source11 https://www.asco.org/practice-patients/guidelines/guideline-methodology |
| Classification of four types of organizations, from announcement to approval and guideline, reports of Figure 2 institutions | The evaluation of this paper | This article by |
| Number of participants in 2026, status of approval after each LBA, number of employees and financial figures of ASCO | Undetermined / Future | Not listed on the official page of this article. This article does not estimate |
| Chapter 6 Prospects 3 Items | Interpre of this paper from 5, 7, 8, 11 |
Last Updated:September 26, 2026/Troy Technical
This document is based on ASCO's official website and news release. The results of clinical trials published by the Society do not mean the use of the clinical trials or approvals. This is an interpretation that reads from primary information. This article is not medical advice.